---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-070554"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T00:52:41.254440+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025

## Summary
- Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.
- Narsoplimab BLA PDUFA date extended from Sep 25, 2025 to Dec 26, 2025; labeling discussions planned by Oct 2025.
- Advanced partnership discussion: potential multi-billion transaction value excl. royalties; upfront would repay $67.1M term loan and $17.1M notes.
- Cash and equivalents $26.0M as of July 18; 61.8M shares outstanding.
- PDE7 inhibitor program: preclinical studies for cocaine use disorder completed; FDA requests more preclinical info.

## SEC filing metadata
- accession: 0001104659-25-070554
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000110465925070554/0001104659-25-070554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000110465925070554/tm2516030d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-070554
- JSON: https://secwatch.observer/filing/0001104659-25-070554.json
- Plain text: https://secwatch.observer/filing/0001104659-25-070554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.